Back

TCR/CD3-based synthetic antigen receptors (TCC) convey superior antigen sensitivity combined with high fidelity of activation

Peters, T.; Muehlgrabner, V.; Velasco Cardenas, R. M. H.; Platzer, R.; Gohring, J.; Salzer, B.; Plach, A.; Hoehrhan, M.; Doel-Perez, I.; Goncalves, V. D. R.; Farfan, J. S.; Lehner, M.; Stockinger, H.; Schamel, W. W.; Schober, K.; Busch, D. H.; Hudecek, M.; Dushek, O.; Minguet, S.; Huppa, J. B.

2023-03-17 immunology
10.1101/2023.03.16.532775 bioRxiv
Show abstract

Low antigen sensitivity and a gradual loss of effector functions limit the clinical applicability of chimeric antigen receptor (CAR)-modified T-cells and call for alternative antigen receptor designs for effective T-cell-based cancer immunotherapy. Here we applied advanced microscopy to demonstrate that TCR/CD3-based synthetic constructs (TCC) outperform second-generation CAR formats with regard to conveyed antigen sensitivities by up to a thousand-fold. TCC-based antigen recognition occurred without adverse non-specific signaling, which is typically observed in CAR-T-cells, and did not depend - unlike sensitized peptide/MHC detection by conventional T-cells - on CD4- or CD8- coreceptor engagement. TCC-endowed signaling properties may prove critical when targeting antigens in low abundance and aiming for a durable anti-cancer response.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.